PriceTargets.com logo

NASDAQ:ANGN - Angion Biomedica Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.33
  • Forecasted Upside: 464.01 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.52 As of 09/17/2021 01:00 AM ET
▼ -0.48 (-4.36%)

This chart shows the closing price for ANGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Angion Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANGN

Analyst Price Target is $59.33
▲ +464.01% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Angion Biomedica in the last 3 months. The average price target is $59.33, with a high forecast of $100.00 and a low forecast of $38.00. The average price target represents a 464.01% upside from the last price of $10.52.

This chart shows the closing price for ANGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Angion Biomedica.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/13/2021HC WainwrightReiterated RatingBuy$100.00Medium
8/31/2021HC WainwrightReiterated RatingBuy$100.00Low
8/3/2021HC WainwrightReiterated RatingBuy$100.00High
6/30/2021HC WainwrightReiterated RatingBuy$100.00High
3/31/2021OppenheimerReiterated RatingBuy$38.00Low
3/2/2021OppenheimerInitiated CoverageOutperform$38.00High
3/2/2021Stifel NicolausInitiated CoverageBuy$40.00High
3/2/2021CowenInitiated CoverageOutperformHigh
3/1/2021HC WainwrightInitiated CoverageBuy$100.00Low
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/22/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Angion Biomedica logo
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York.
Read More

Today's Range

Now: $10.52
Low: $10.07
High: $11.36

50 Day Range

MA: $10.89
Low: $9.31
High: $13.25

52 Week Range

Now: $10.52
Low: $9.03
High: $26.30

Volume

1,785,800 shs

Average Volume

128,078 shs

Market Capitalization

$313.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Angion Biomedica?

The following Wall Street research analysts have issued research reports on Angion Biomedica in the last twelve months: Cowen Inc, HC Wainwright, Oppenheimer Holdings Inc., Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for ANGN.

What is the current price target for Angion Biomedica?

3 Wall Street analysts have set twelve-month price targets for Angion Biomedica in the last year. Their average twelve-month price target is $59.33, suggesting a possible upside of 464.0%. HC Wainwright has the highest price target set, predicting ANGN will reach $100.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $38.00 for Angion Biomedica in the next year.
View the latest price targets for ANGN.

What is the current consensus analyst rating for Angion Biomedica?

Angion Biomedica currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANGN will outperform the market and that investors should add to their positions of Angion Biomedica.
View the latest ratings for ANGN.

What other companies compete with Angion Biomedica?

Other companies that are similar to Angion Biomedica include MacroGenics, Fulcrum Therapeutics, Heron Therapeutics, Antibe Therapeutics, Enanta Pharmaceuticals, ImmunoGen, Repare Therapeutics, RAPT Therapeutics, ChemoCentryx, Janux Therapeutics, Arcutis Biotherapeutics, Precigen, MannKind, Northwest Biotherapeutics and Axsome Therapeutics.

How do I contact Angion Biomedica's investor relations team?

Angion Biomedica's physical mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The company's listed phone number is 415-655-4899 and its investor relations email address is [email protected] The official website for Angion Biomedica is www.angion.com.